Current treatment status-Undergoing active treatment-No response Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-No response Posts on Medivizor

Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Posted by on Nov 22, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the long-term effectiveness of fixed-duration treatment with venetoclax (Venclexta) plus rituximab (Rituxan) in patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that fixed-duration treatment with venetoclax plus rituximab was effective over the long term in these...

Read More

Evaluating the safety and effectiveness of tebentafusp in previously treated patients with advanced uveal melanoma

Evaluating the safety and effectiveness of tebentafusp in previously treated patients with advanced uveal melanoma

Posted by on Oct 25, 2022 in Melanoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of tebentafusp (Kimmtrak) in patients with metastatic uveal melanoma who had received previous treatments. The study found that tebentafusp had promising effectiveness and a good safety profile in these patients. Some background Uveal melanoma is a rare and aggressive eye tumor....

Read More

Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia

Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia

Posted by on Sep 27, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to compare salvage intensive chemotherapy (IC) and a venetoclax (Venclexta; VEN)-combined low-intensity regimen in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML).   This study concluded that the VEN-combined regimen provided similar responses and survival rates when compared to...

Read More

Evaluating outcomes after salvage therapy using chemotherapy or allogeneic stem cell transplantation for unresponsive acute myeloid leukemia

Evaluating outcomes after salvage therapy using chemotherapy or allogeneic stem cell transplantation for unresponsive acute myeloid leukemia

Posted by on Sep 17, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of salvage treatment using either chemotherapy (CT) or allogeneic hematopoietic stem cell transplant (allo-HSCT) on the overall outcome in patients with refractory (unresponsive) acute myeloid leukemia (AML).  This study concluded that allo-HSCT benefits these patients and that direct...

Read More

Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

Posted by on May 8, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed or refractory (r/r) follicular lymphoma (FL). The data showed that pembrolizumab in combination with rituximab was safe and effective in these patients. Some background Follicular lymphoma (FL)...

Read More

Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.

Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.

Posted by on Nov 27, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness of talimogene laherparepvec (Imlygic; T-VEC) after failure of immunotherapy for the treatment of patients with unresectable metastatic melanoma. The data showed that T-VEC after the failure of immunotherapy is safe and effective in these patients. Some background Melanoma is an aggressive type of...

Read More

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

Posted by on Nov 21, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL). The study showed that this medication has promising effectiveness and safety in these patients.  Some background B-NHL is a type of...

Read More

Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.

Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.

Posted by on Aug 22, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of pembrolizumab (Keytruda) plus GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) as second-line therapy for patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the pembrolizumab plus GVD combination is safe and highly effective...

Read More

Evaluating the long-term effectiveness and safety of tandem CAR T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma.

Evaluating the long-term effectiveness and safety of tandem CAR T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma.

Posted by on Aug 22, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term safety and effectiveness of tandem chimeric antigen receptor (tCAR) T-cell therapy for patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The data showed that tCAR T-cell therapy resulted in long-term remission rates with manageable side effects for these patients. Some...

Read More

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Posted by on Aug 15, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including non-Hodgkin lymphoma (NHL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial...

Read More

Evaluating dual-target CAR T-cell therapy for patients with unresponsive B-cell NHL

Evaluating dual-target CAR T-cell therapy for patients with unresponsive B-cell NHL

Posted by on Aug 8, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of dual chimeric antigen receptor (CAR) T-cell therapy for patients with recurrent or hard-to-treat B-cell non-Hodgkin lymphoma (NHL). This study found that this treatment was safe and effective for these patients. Some background B-cell non-Hodgkin’s lymphoma (NHL) is one of...

Read More

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma/leukemia?

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma/leukemia?

Posted by on Jul 31, 2021 in Leukemia | 0 comments

In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was...

Read More